

DOCKET NO.: 214201US0 DIV

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :
Hiroyuki ISHIWATA, et al. : ATTN: APPLICATION DIVISION
SERIAL NO.: NEW APPLICATION :
FILED: HERewith :
FOR: DIAMIDE COMPOUND AND MEDICINE CONTAINING THE SAME

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE SPECIFICATION

On page 1, at the top of the page, delete "DESCRIPTION" and insert therefor:

--TITLE OF THE INVENTION--

On page 1, in the title, delete "comprising" and insert therefor: --containing--.

On page 1, line 22 from the bottom of the page delete "TECHNICAL FIELD" and insert therefor: --Field of the Invention--.

On page 1, line 17 from the bottom of the page, delete "BACKGROUND ART" and insert therefor: --Description of the Background--.

On page 2, under line 20, insert: --SUMMARY OF THE INVENTION--.

On page 2, last line, delete "DISCLOSURE OF THE INVENTION" and insert therefor:

--DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT--.

On page 7, substitute the paragraph beginning on the last line with the following:

--The diamide compounds (1) may also be present in the form of a solvate.--


On page 103, line 1, delete "ABSTRACT" and insert therefor: --ABSTRACT OF THE DISCLOSURE--.

IN THE CLAIMS

Please cancel Claims 1-13.

Please add new Claims 14-26:


--14. (New) A compound represented by the following general formula (1):




wherein:

A is a phenyl, naphthyl, dihydronaphthyl, indenyl, pyridyl, indolyl, isoindolyl, quinolyl or isoquinolyl group, any of which may be substituted;

B is a group of $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-(\text{CH}=\text{CH})_2-$, $-\text{CH}=\text{CH}-\text{C}\equiv\text{C}-$ or $-\text{C}\equiv\text{C}-\text{CH}=\text{CH}-$, or a divalent residue of benzene, pyridine, pyrimidine or pyrazine, any of which may be substituted; and



in which X is



wherein Y^1 , Y^2 and Y^3 are each independently selected from the group consisting of

a hydrogen atom,

$-\text{COOR}^1$, wherein R^1 is a hydrogen atom or a lower alkyl group,

$-\text{CON}(\text{R}^2)\text{R}^3$, wherein R^2 and R^3 are each independently selected from the group

consisting of a hydrogen atom, a hydroxyl group, and a lower alkyl group,

$-\text{CH}_2\text{N}(\text{R}^4)\text{R}^5$, wherein R^4 and R^5 are each independently a hydrogen atom or a lower alkyl group, or R^4 and R^5 may form, together with the adjacent nitrogen atom, a heterocyclic ring which may further have an oxygen, nitrogen or sulfur atom, and

$-\text{CH}_2-\text{S}-\text{R}^6$, wherein R^6 is a lower alkyl, phenyl or pyridyl group; or

Y^1 and Y^2 may couple to each other to form an alkylene group which may be through an oxygen, nitrogen or sulfur atom,

Z is a benzene or pyridine ring, and

n is an integer of 2 or 3,

with the proviso that when B is a p-phenylene group, and W is a 1,4-piperazinyl group, A is not a phenyl group, and when B is $-\text{CH}=\text{CH}-$, A is not a phenyl group which may be substituted,

or a salt thereof, or a hydrate or solvate thereof.

15. (New) The compound according to Claim 14, wherein A is a phenyl, naphthyl, dihydronaphthyl, indenyl, pyridyl, indolyl, isoindolyl, quinolyl or isoquinolyl group any of which may have 1-3 substituents independently selected from the group consisting of a hydroxyl group, a halogen atom, a lower alkyl group which may be substituted by 1-3 halogen atoms, a lower alkoxy group, an amino group which may be substituted by one or two lower alkyl groups, and a lower alkylthio group.

16. (New) A composition comprising the compound according to Claim 14 and a pharmaceutically acceptable carrier.

17. (New) The composition according to Claim 16 in solid, semi-solid or liquid form.
18. (New) The composition according to Claim 16 in the form of a tablet, pill, granule, soft capsule, hard capsule, powder, grain, trituration, emulsion, syrup, pellet or elixir.
19. (New) The composition according to Claim 16 in the form of an injection, drop, infusion, ointment, lotion, tonic, spray, inhalation suspension, oil, emulsion or suppository.
20. (New) The composition according to Claim 16, wherein said carrier comprises a surfactant, excipient, colorant, smell corrigent, preservative, stabilizer, buffer, suspension stabilizer, or isotonic agent.
21. (New) The composition of Claim 16, wherein said compound is an acid-addition salt, a solvate or a hydrate.
22. (New) A method for inhibiting the production of an IgE antibody comprising administering an amount of the compound of Claim 14 suitable for inhibiting the production of IgE.
23. (New) The method of Claim 22 that is an *in vivo* method.
24. (New) A method for treating an allergic immunological disease comprising administering an effective amount of the compound of Claim 14 to a subject in need thereof.
25. (New) The method of Claim 24, wherein said allergic immunological disease is selected from the group consisting of asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease or contact dermatitis.
26. (New) The method of Claim 24, wherein said effective amount ranges from 0.01-1,000 mg/kg/day.--

REMARKS

Claims 14-26 are pending. These claims find support in original Claims 1-13.


Additional support for the compositions of Claims 16-21 is found in the disclosure on page 10,

lines 4-21. Additional description of the methods of Claims 22-26 is found in the disclosure in the paragraph bridging pages 9 and 10 and in Test Example 1 on pages 97-99. Support for the correction to page 7 of the specification is found in the disclosure in lines 5-7 from the bottom of page 9. Accordingly, the Applicants do not believe that any new matter has been added.

CONCLUSION

The Applicants submit that Claims 14-26 are now in condition for early examination on the merits.

Respectfully submitted,
OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon
Attorney of Record
Registration No.: 24,618

Thomas M. Cunningham, Ph.D.
Registration No.: 45,394

Tel.: 703-413-3000
Fax: 703-413-3220
NFO:TMC:ksh
I:\atty\Tmc\214201-Prel Amend.wpd



22850

Marked-up Copy

Docket No.: 214201US0 DIV

Serial No.: NEW APPLICATION

Amendment Filed: HEREWITH

IN THE SPECIFICATION

On page 1, at the top of the page, delete "DESCRIPTION" and insert therefor:

--TITLE OF THE INVENTION--

On page 1, in the title, delete "comprising" and insert therefor: --containing--.

On page 1, line 22 from the bottom of the page delete "TECHNICAL FIELD" and insert therefor: --Field of the Invention--.

On page 1, line 17 from the bottom of the page, delete "BACKGROUND ART" and insert therefor: --Description of the Background--.

On page 2, under line 20, insert: --SUMMARY OF THE INVENTION--.

On page 2, last line, delete "DISCLOSURE OF THE INVENTION" and insert therefor:

--DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT--.

On page 7, substitute the paragraph beginning on the last line with the following:

--The diamide compounds (1) may also be present in the form of a solvate--.

On page 103, line 1, delete "ABSTRACT" and insert therefor: --ABSTRACT OF THE DISCLOSURE--.

IN THE CLAIMS

Please cancel Claims 1-13.

Please add new Claims 14-26:

2025-03-10 10:00

--14. (New)

15. (New)

16. (New)

17. (New)

18. (New)

19. (New)

20. (New)

21. (New)

22. (New)

23. (New)

24. (New)

25. (New)

26. (New).--

